Numinus Wellness Inc (TSE:NUMI) has released an update.
Numinus Wellness Inc. has applied for a Health Canada clinical trial to investigate group-based MDMA-assisted psychotherapy, focusing on safety and determining the ideal number of therapists. This research could pioneer group therapy practices for treating serious mental health conditions and enhance practitioner training. Numinus stands at the forefront of integrating psychedelic-assisted therapies into mainstream healthcare for various mental ailments.
For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.
